CONFERENCE UPDATE: NDF 2021
The evolving treatment landscape of high-risk MM
With major advances in the management of multiple myeloma (MM), next-generation proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies were approved for the treatment of relapsed/refractory MM (rrMM).1 However, Prof. Chim, Chor-Sang James noted that most patients who developed advanced rrMM are refractory to many treatment agents, and anti-CD38 monoclonal antibodies and other immunotherapies are the most important treatment options left for these patients.
Where the anti-CD38 antibody isatuximab is currently under study, other emergent treatment options that target the B-cell maturation antigen (BCMA) have yielded deep responses in rrMM.1 Importantly, BCMA is a cell surface protein that is universally expressed on malignant plasma cells, enabling a highly selective treatment target specifically for MM treatment.2 As such, BCMA-targeting antibody-drug conjugate (ADC), bispecific T-cell engager (BiTE) and chimeric antigen receptor T-cell (CAR-T) therapy are being developed to address the unmet needs of rrMM patients. Of the BCMA-targeting treatment options, the phase 1 dose-escalation CRB-401 study showed that a sufficient amount (≥150x106 cells) of the anti-BCMA CAR-T therapy, idecabtagene (bb2121), induced a dose-dependent response with a median progression-free survival (PFS) of 11.8 months in patients who had very advanced disease and a median of 8 prior regimens.3 In the follow-up phase 2 KarMMa study, idecabtagene also showed a dose-dependent survival benefit with a median overall survival (OS) of 19.4 months in heavily pre-treated patients.4
Similarly, the phase 1b/2 CARTITUDE-1 study showed that another anti-BCMA CAR-T, LCAR-B38M/JNJ-4528, was able to achieve a 6-month PFS in 93% of patients who had a median of 5 prior lines of therapy (86% and 31% of patients are triple and penta-refractory, respectively).5 Importantly, an impressive objective response rate (ORR) of 100% was achieved, with 76% of patients achieving stringent complete response and 21% achieving very good partial response.5
From a safety perspective, Prof. Chim noted that while cytokine release syndrome (CRS) is an expected side effect of CAR-T in MM patients due to its mechanism of action, multiple studies showed that MM patients have a comparatively better safety profile than those with B-cell acute lymphoblastic leukemia (ALL), diffuse large- B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). In the ZUMA-1 study, 11% and 32% of large B-cell lymphoma patients have experienced ≥grade 3 CRS and neurological events, respectively, after receiving the anti-CD19 CAR-T axicabtagene ciloleucel (KTE-C19).6 Comparatively, MM patients in the CRB-401 study had a much lower rate of ≥grade 3 CRS and neurological events of 6% and 3%, respectively.3 In the CARTITUDE-1 study, 93% of patients had experienced CRS, yet only 7% of these patients experienced ≥grade 3 CRS.5 “Compared to other forms of blood cancer receiving CAR-T, MM is a privileged entity with a low rate of severe CRS or neurotoxicity,” commented Prof. Chim.
As CAR-T is a potentially highly effective yet toxic treatment for MM, Prof. Chim urged that high-risk MM patients should be identified to assess whether upfront CAR-T therapy is warranted. To identify these patients, Prof. Chim recommended the inclusion of a cytogenetic scoring system (CSS) that can identify patients who had an OS of <3 years despite bortezomib-based induction therapy and hence warrant a clinical trial with upfront CAR-T. Under this scoring system, high-risk patients with a CSS score of >1 can be enrolled into clinical trials and receive induction with anti-CD38 antibodies. Allogeneic hematopoietic stem-cell transplantation (HSCT) can then be given in tandem for patients with del(17p) according to the mSMART guidelines, and CAR-T can be given to patients as consolidation.
New ‘KdD’ triple drug combination enhances clinical efficacy in the treatment of relapsed/refractory myeloma
There has been a shift in the treatment paradigm for relapsed/refractory (R/R) multiple myeloma (MM) over the last decade due to the emergence of novel drugs and combination regimens. At the recent American Society of Hematology (ASH) Annual Meeting 2019,
The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival
Multiple myeloma (MM) is a type of clonal neoplasm with substantial morbidity and mortality. With the development of better therapies, MM has transformed from untreatable to still incurable but treatable.1
Management of multiple myeloma in Hong Kong
Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies.1 In Hong Kong, the majority of MM patients are older than 65-years-old. Management of these patients needs special consideration due to age-related comorbidities.
Belantamab mafodotin-blmf: A potential new candidate in combination treatment for patients with relapsed or refractory multiple myeloma
In the recent DREAMM-2 study, single-agent belantamab mafodotin-blmf has demonstrated anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.1 Based on this result, the United